Web Results

Earnings Roundup: What You Need to Know About Gilead's ...

www.fool.com/investing/general/2014/04/23/earnings-roundup-what-you-need-to-know-about-gilea.aspx

Apr 23, 2014 ... Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing ... Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter ... Olysio's sales totaled $350 million in the first quarter as the drug was ...

Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings - April 26 ...

www.zacks.com/stock/news/214810/biotech-stock-gilead-gild-likely-to-beat-in-q1-earnings

Apr 26, 2016 ... Gilead Sciences (GILD), which is set to report first-quarter 2016 results on ... Gilead's blockbuster hepatitis C virus (HCV) drug Harvoni should continue to ... Here are a couple of other health care stocks that you may want to ... Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data.

Gilead Sciences: After Hepatitis C Court Victory, an Earnings Boost ...

blogs.barrons.com/stockstowatchtoday/2016/06/08/gilead-sciences-after-hepatitis-c-court-victory-an-earnings-boost/

Jun 8, 2016 ... Late Tuesday, Gilead Sciences (GILD) won a court ruling in its battle with Merck ... property rights behind its blockbuster hepatitis-C drugs Harvoni and Sovaldi. ... News and commentary about the stocks you need to know about today ... 2016 but generated only $50 million of sales in the first quarter of 2016.

Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in ...

www.nasdaq.com/article/biotech-stock-roundup-gilead-hiv-drug-approved-baxalta-in-immuno-oncology-deal-cm587513

Mar 2, 2016 ... The fourth quarter earnings season is winding down, with quite a few ... The sooner you can start, the better ... Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in ... HIV treatments to market and to boost sales of its blockbuster HIV ... T cell therapies targeting areas of major unmet need in cancer.

Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in ...

finance.yahoo.com/news/biotech-stock-roundup-amgen-impresses-171105755.html

May 4, 2016 ... Big names in the biotech sector reported earnings over the last five trading ... Vertex's first quarter results were also disappointing with the ... According to AbbVie, the candidate has blockbuster potential and ... The company plans to speed up its efforts to bring new treatments .... Know how many I've done?

Lions Gate Partners With Vimeo to Enhance Online Services.

finance.yahoo.com/news/lions-gate-partners-vimeo-enhance-130301211.html

Sep 14, 2016 ... Beyond this Analyst Blog, would you like to see Zacks' best .... Apple Car rumor roundup: Here's everything you need to know about 'Project Titan' .... its third- quarter earnings, which it expects to announce late next month. ... In the near term, Gilead investors should take a more bullish view of the s...

The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The ...

finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-133001456.html

Jun 30, 2016 ... Biotech Stock Roundup ... Meanwhile, Gilead continues to expand its blockbuster HCV franchise. ... and will focus on submitting a NDA in the fourth quarter of 2016 . .... Yahoo Confirms Massive Data Breach: What You Need to Know ..... be a better indicator of your future employability and earnings potential.

Stock Quote TBRA Tobira Therapeutics, Inc. - Finviz

finviz.com/quote.ashx?t=TBRA

Income, -57.20M, PEG, -, EPS next Q, -0.64, Inst Own, 70.50%, Short Float, 2.53 % ... Sep-22-16 04:35PM, Gilead, Allergan Seen Trailing Intercept In Ongoing ... 08:39AM, Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA ... 04: 00PM, STOCKS DO NOTHING AHEAD OF THE FED: Here's what you need to know.

News Article Archive from May 24, 2016 - Wsj.com

www.wsj.com/public/page/archive-2016-5-24.html

May 24, 2016 ... But a mix of accounting and politics could cause one or both to need another taxpayer .... that the continuing labor strike may impact its second-quarter results. ... Intuit Reports Better-Than-Expected Earnings ... Gilead Names New Operating Chief Gilead Sciences Inc. on ..... Here is what you need to know.

Biotechnology and Pharmaceuticals - CNBC.com

www.cnbc.com/biotech-and-pharmaceuticals/

Blockbuster biotech deal coming? ... The cost of naloxone has spiraled upwards, even as the drug has become more desperately needed to reverse overdoses.

More Info

Lower Harvoni sales dampen Gilead's second-quarter profit ...

www.modernhealthcare.com

Jul 25, 2016 ... Drugmaker Gilead Sciences saw its earnings fall again amid lower sales of its expensive blockbuster hepatitis C drug Harvoni. ... Reduced sales of Harvoni also affected Gilead's profits last quarter, ... When you combine this change with industry consolidation and payer shifts, the uncertainty can be... More .....

Gilead Sciences: Going, Going… - Stocks to Watch - Barrons.com

blogs.barrons.com

Aug 10, 2016 ... Despite the fact that Gilead Sciences (GILD) hepatitis C treatments are as ... News and commentary about the stocks you need to know about today ... This is the second quarter in a row where total market sales have ... Which begs the question: Has a blockbuster drug ever been more of .... Income Investing ...

Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead

www.nasdaq.com

Mar 15, 2016 ... Anyone following biotech stocks will know that the sector, which has ... In addition to having several blockbuster products in its portfolio which should ... This Zacks Rank #5 stock missed earnings expectations in three of the last four quarters ... Today, you can download 7 Best Stocks for the Next 30 Days.